Ignite Creation Date:
2025-12-24 @ 10:41 PM
Ignite Modification Date:
2026-01-05 @ 1:39 PM
Study NCT ID:
NCT00679835
Status:
COMPLETED
Last Update Posted:
2019-11-13
First Post:
2008-05-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections
Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-06-03
Start Date Type:
ACTUAL
Primary Completion Date:
2008-11-20
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-11-20
Completion Date Type:
ACTUAL
First Submit Date:
2008-05-15
First Submit QC Date:
None
Study First Post Date:
2008-05-19
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-11-11
Last Update Post Date:
2019-11-13
Last Update Post Date Type:
ACTUAL